知镜 Cognispect · 医学文献与研究工作台

A 177Lu-Labeled Circular Bivalent Aptamer for PTK7-Targeting Radionuclide Therapy in Ovarian Cancer and Orthotopic Hepatoblastoma.

Tong X, He Y, Liu H, Guo W, Huang WG, Li P, Wang L, Zhu Y, Cai L, Yi HQ, Wang XQ, Tan W.
Journal of medicinal chemistry · 2026-09-01 · PMID 42720498

文献摘要

Targeted radionuclide therapy (TRT) is a promising strategy for precision oncology but is limited by the lack of high-performance targeting ligands. Here, we report a lutetium-177 (177Lu)-labeled PTK7-targeted cyclized bivalent aptamer (CBSgc8) for treating an orthotopic hepatoblastoma. The cyclized multivalent design enhances biostability and binding affinity, while 177Lu labeling preserves its functional properties. The resulting 177Lu-CBSgc8 exhibited high serum stability, strong specificity for PTK7-positive cells, efficient internalization, and dose-dependent cytotoxicity in vitro. In vivo, 177Lu-CBSgc8 inhibited tumor growth in an OVCAR3 ovarian cancer model, although tumor accumulation remained limited. Given its PTK7-targeting capability and preferential hepatic distribution, we further evaluated its therapeutic potential in an orthotopic HepG2 hepatoblastoma model. In this setting, 177Lu-CBSgc8 achieved 76.6% tumor growth inhibition with a favorable safety. These findings demonstrate the potential of exploiting tissue distribution characteristics together with molecular targeting to expand the applicability of aptamer-based TRTs.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。